Improving lives with innovative value-added medicines
Welcome to the Hyloris investor relations pages.
Creating value by rethinking and reinventing existing medications
Our ambition is to develop added-value medicines based on known pharmaceuticals to address unmet medical needs and deliver improvements for patients, healthcare professionals and payors.
By 2024, our vision is that our portfolio of candidate and commercial value-added products will have grown to 30.
Founded in Liège, Belgium in 2012, Hyloris Pharmaceuticals SA’s ordinary shares are listed on Euronext Brussels since June 2020, under the ticker symbol HYL and are included in the Bel Small Cap index.
The Hyloris share +
View the interactive share price graph, the shareholding structure, and more share related information here.
Consult our financial reports, the financial calendar, and other documents here.
Our governance +
Information about our corporate governance principles, our governance structure and documents can be found here.